Outcomes by transarterial chemoembolization (TACE) modality from participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D)+bevacizumab (B)+TACE and placebos (PBO)+TACE: EMERALD-1 subgroup analysis | Publicación